中性粒细胞减少症预防和治疗回顾

李 苑1, 林 明哲2
1、青海大学附属医院
2、青海大学附属医院肿瘤内科

摘要


化疗诱导的中性粒细胞减少症（CIN）是癌症治疗中常见且严重的不良反应，主要由化疗药物对骨髓造血
干细胞的抑制作用引起。CIN显著增加了感染风险，特别是在化疗后 7至 14天之间，并可能导致发热性中性粒细胞
减少症（FN）。常见的预防措施包括使用风险评估工具（如MASCC评分）和粒细胞集落刺激因子（G-CSF），后者
通过促进中性粒细胞生成来增强免疫防御。此外，新药Trilaciclib在预防 CIN方面表现出潜力。全面的评估和管理策
略对于实现 CIN治疗的个体化至关重要，强调了在癌症治疗中平衡抗癌效果和患者安全的必要性。

关键词


化疗；中性粒细胞减少症；抗生素；曲拉西利

全文:

PDF


参考


[1]Flowers C R, Seidenfeld J, Bow E J, et al. Antimicrobial

Prophylaxis and Outpatient Management of Fever and

Neutropenia in Adults Treated for Malignancy: American

Society of Clinical Oncology Clinical Practice Guideline[J].

Journal of Clinical Oncology, 2013, 31(6): 794-810.

[2]Koenig C, Schneider C, Morgan J E, et al. Association

of time to antibiotics and clinical outcomes in patients with

fever and neutropenia during chemotherapy for cancer: a

systematic review[J]. Supportive Care in Cancer, 2020, 28(3):

1369-1383.

[3]Crawford J, Dale D C, Lyman G H. Chemotherapy‐

induced neutropenia: Risks, consequences, and new directions

77

现代医学前沿 | 第2卷/第11期

Advances in Mordern Medical

for its management[J]. Cancer, 2004, 100(2): 228-237.

[4]Talcott J A, Siegel R D, Finberg R, et al. Risk

assessment in cancer patients with fever and neutropenia: a

prospective, two-center validation of a prediction rule.[J].

Journal of Clinical Oncology, 1992, 10(2): 316-322.

[5]Aapro M S, Cameron D A, Pettengell R, et al.

EORTC guidelines for the use of granulocyte-colony

stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas

and solid tumours[J]. European Journal of Cancer, 2006,

42(15): 2433-2453.

[6]Klastersky J, De Naurois J, Rolston K, et al.

Management of febrile neutropaenia: ESMO Clinical Practice

Guidelines[J]. Annals of Oncology, 2016, 27: v111-v118.

[7]Pizzo P A. Management of Patients With Fever

and Neutropenia Through the Arc of Time: A Narrative

Review[J]. Annals of Internal Medicine, 2019, 170(6): 389.

[8 ]Kelly S, Wheatley D. P revention of feb rile

neutropenia: use of granulocyte colony-stimulating factors[J].

British Journal of Cancer, 2009, 101(S1): S6-S10.

[9]Link H. Current state and future opportunities in

granulocyte colony-stimulating factor (G-CSF)[J]. Supportive

Care in Cancer, 2022, 30(9): 7067-7077.

[10]Lyman G H, Kuderer N M, Djulbegovic B.

Prophylactic granulocyte colony-stimulating factor in patients

receiving dose-intensive cancer chemotherapy: a metaanalysis[J]. The American Journal of Medicine, 2002, 112(5):

406-411.

[11]Aapro M, Crawford J, Kamioner D. Prophylaxis of

chemotherapy-induced febrile neutropenia with granulocyte

colony-stimulating factors: where are we now?[J]. Supportive

Care in Cancer, 2010, 18(5): 529-541.

[12 ] Lym a n G H. G ui d eli n e s of t h e N ati o n al

Comprehensive Cancer Network on the Use of Myeloid

Growth Factors with Cancer Chemotherapy: A Review of

the Evidence[J]. Journal of the National Comprehensive

Cancer Network, 2005, 3(4): 557-571.

[13]Crawford J, Caserta C, Roila F. Hematopoietic

growth factors: ESMO Clinical Practice Guidelines for the

applications[J]. Annals of Oncology, 2010, 21: v248-v251.

[14]Slavin M A, Lingaratnam S, Mileshkin L, et al. Use

of antibacterial prophylaxis for patients with neutropenia[J].

Internal Medicine Journal, 2011, 41(1b): 102-109.

[15]宋德旭，高萱，窦鹏挥.曲拉西利的临床研究进

展 [J].广东化工，2023，50（16）：92-93，102.

[16]Myeloid Growth Factors Clinical Practice Guidelines

in Oncology[J]. Journal of the National Comprehensive

Cancer Network, 2005, 3(4): 540.

[17]宋慧娜，方英立，李际盛.曲拉西利在小细胞肺

癌药物治疗中的骨髓保护作用 [J].上海医药，2024，45

（5）：65-69.

[18]郑雪晴，张力，张晓彤.细胞周期蛋白依赖性激

酶 4/6抑制剂曲拉西利抗肿瘤作用机制及临床研究进展

[J].中国新药杂志，2023，32（23）：2329-2338.

[19]Parylo S, Vennepureddy A, Dhar V, et al. Role

of cyclin-dependent kinase 4/6 inhibitors in the current

and future eras of cancer treatment[J]. Journal of Oncology

Pharmacy Practice, 2019, 25(1): 110-129


Refbacks

  • 当前没有refback。